TICKERNERD
Menu
AUPHAUPHHealthcare · Biotechnology

AUPH Stock Forecast: Aurinia Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Sept 2026
$16
−0.06% on the day

The 6 Wall Street analysts covering Aurinia Pharmaceuticals, Inc. hold a median 12-month price target of $17 — +5.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 7 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.1B
Ticker Nerd rank
92 / 100
Median analyst target
$17
Analysts covering
6
Revenue$83.2M+18.9% y/y
Operating income$46.3M
Net income$37.4M
Free cash flow$52.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
+1.4%
YTD
+0.8%
1Y
+30.7%
From 52W high
−13.7%
From 52W low
+45.4%
$11
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AUPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aurinia Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
97
Issuance
91
Volatility
87
Growth
82
Momentum
73
Revisions
53
Size
35
Accruals
22

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

The Ticker Nerd Read

Top-decile value and quality carry the rank; accruals hold it back.

As of 7 September 2026, our factor model ranks Aurinia Pharmaceuticals 92.4 of 100 across roughly 4,600 US stocks, and 17th of 527 biotechnology companies. The rank rides on very strong Value (99.2), Quality (96.5) and Debt/Equity Issuance (91.5) readings: the price is low relative to what the business earns and owns, profitability is high, and management has been buying back stock. The counterweight is Investment/Accruals at 21.7, with an earnings-quality subscore of 15.9, and Estimate Revisions sits mid-pack at 53.5.

As of 8 September 2026, analysts' median price target is $17 against the 4 September 2026 close of $16.08, with five buy ratings, one hold and no sells among six analysts. That consensus is constructive but guarded, and its own numbers have been drifting down: consensus next-year EPS of $1.07 is 4.6% below where it stood 90 days earlier. The shares are up 28.3% over twelve months to 4 September 2026, versus 20.0% for the S&P 500 over the same window.

The accruals drag traces to the December 2025 quarter, when net income of $210.8 million far exceeded operating income of $33.2 million. In the June 2026 quarter, operating cash flow of $52.6 million ran above net income of $37.4 million; a repeat of a large below-the-line gain would keep the drag in place. The patent settlement Aurinia announced with Teva on 20 August 2026 pushes potential US generic competition for voclosporin out to December 2036, and pipeline readouts on aritinercept and the phase 4 PRESERVE trial are the threads most likely to move analyst estimates.

As of 8 Sept 2026
Wall Street

AUPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AUPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18$20$22Oct 25Jan 26Apr 26Jul 26AUPHHigh $21Median $17Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $16Median $17High $21

The green dot is the last close — the median target sits +5.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsSector Perform$15 → $16
3 Dec 2025Leerink PartnersDowngradeMarket Perform—
3 Dec 2025Leerink PartnersDowngradeMarket Perform$15 → $16
7 Nov 2025JefferiesUpgradeBuy—
5 Nov 2025RBC CapitalDowngradeSector Perform—
1 Aug 2025RBC CapitalMaintainsOutperform—
30 July 2025HC Wainwright & Co.AssumesBuy$17
16 Sept 2024Cantor FitzgeraldReiteratesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.ReiteratesBuy—
23 Feb 2024Cantor FitzgeraldMaintainsOverweight—
22 Feb 2024HC Wainwright & Co.MaintainsBuy—
16 Feb 2024RBC CapitalMaintainsOutperform—
22 Sept 2023HC Wainwright & Co.ReiteratesBuy—
7 Aug 2023HC Wainwright & Co.MaintainsBuy$14 → $15
7 Aug 2023HC Wainwright& Co.MaintainsBuy—
6 July 2023Cantor FitzgeraldReiteratesOverweight—
3 May 2023HC Wainwright & Co.ReiteratesBuy—
23 Feb 2023RBC CapitalReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AUPH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AUPH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Sept 2026, Aurinia Pharmaceuticals, Inc. returned +30.7% against +19.4% for the S&P 500, dividends included.

AUPH vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Oct 25Jan 26Apr 26Jul 26AUPHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AUPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.7%
Analysts raising
1
Analysts cutting
2
Fundamentals

Aurinia Pharmaceuticals, Inc. (AUPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.1×

Cheaper than 63% of US stocks

Price / sales
6.9×

Cheaper than 19% of US stocks

Price / book
3.5×

Cheaper than 30% of US stocks

EV / EBITDA
9.8×

Cheaper than 39% of US stocks

Growth & margins
Revenue growth (YoY)
18.9%

Higher than 68% of US stocks

Earnings growth (YoY)
73.9%

Higher than 80% of US stocks

Gross margin
92.1%

Higher than 97% of US stocks

Operating margin
55.7%

Higher than 98% of US stocks

Net margin
100.8%

Higher than 99% of US stocks

Returns & dividend
Return on equity
66.1%

Higher than 94% of US stocks

Return on assets
15.5%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aurinia Pharmaceuticals, Inc. (AUPH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aurinia Pharmaceuticals, Inc. has a market value of $2.1B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $311.5M. The latest quarter grew 18.9% year on year.

  • Net income over the same four quarters: $314.1M, a 100.8% net margin.

  • Diluted earnings per share, trailing twelve months: $2.29.

  • Free cash flow in the twelve months to 30 June 2026: $175.1M.

  • Aurinia Pharmaceuticals, Inc. spent $83.6M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 132.9M.

  • Trailing P/E: 7.1×; forward P/E: 15.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Aurinia Pharmaceuticals, Inc. employs 128 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

AUPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AUPHAurinia Pharmaceuticals, Inc.$2.1B
92
URGNUroGen Pharma Ltd.$2.1B
77
KODKodiak Sciences, Inc.$2.1B
45
ADMAADMA Biologics, Inc.$2.2B
41
RAPPRapport Therapeutics, Inc.$2.1B
45
GENBGenerate Biomedicines, Inc.$2.1B
0
ZYMEZymeworks, Inc.$2.1B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aurinia Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AUPH news & analysis

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Zacks Investment Research · 20 Aug 2026positive

Aurinia Pharmaceuticals settled its voclosporin patent litigation with Teva. The settlement delays potential generic competition in the United States until December 2036, and the company's stock rose following the news.

Why it matters — AUPH watchers would care because the settlement extends patent protection for voclosporin, reducing near-term generic competition risk for a key product.

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Benzinga · 20 Aug 2026positive

Aurinia Pharmaceuticals has entered into a settlement agreement with Teva Pharmaceutical Industries to resolve a patent dispute related to its kidney disease drug. Aurinia's shares rose in Thursday's premarket trading following the announcement.

Why it matters — The settlement removes patent litigation uncertainty for Aurinia's kidney disease drug, which could affect its competitive position and market outlook.

Aurinia Settles Patent Litigation with Teva

Business Wire · 19 Aug 2026neutral

Aurinia Pharmaceuticals announced it has settled patent litigation with Teva, according to a Business Wire release from Edmonton, Alberta. The settlement resolves the patent dispute between the two companies.

Why it matters — Resolving the patent litigation removes legal uncertainty around Aurinia's patent position that AUPH watchers had been monitoring.

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Seeking Alpha · 12 Aug 2026neutral

Aurinia Pharmaceuticals is advancing its pipeline, running the phase 4 PRESERVE trial in lupus nephritis testing combinations containing its drug Lupkynis, and developing aritinercept across four potential indications. However, Lupkynis could face potential challenges to its market exclusivity in the near future, and the company provides little clarity on timelines for further aritinercept updates.

Why it matters — AUPH watchers would care because this update addresses both the company's pipeline progress and potential risks to the market position of its key drug Lupkynis.

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Zacks Investment Research · 6 Aug 2026positive

Aurinia Pharmaceuticals reported Q2 earnings of $0.28 per share, surpassing the Zacks Consensus Estimate of $0.19 per share and up from $0.16 per share a year ago.

Why it matters — The results indicate Aurinia's quarterly earnings came in well above analyst expectations and improved year over year.

FAQ

Frequently asked questions about AUPH stock

What is the AUPH stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Aurinia Pharmaceuticals, Inc. have a median 12-month price target of $17, with estimates ranging from $16 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AUPH stock a buy right now?

Of the 6 analysts covering Aurinia Pharmaceuticals, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aurinia Pharmaceuticals, Inc. 92 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AUPH?

As at 7 Sept 2026, Aurinia Pharmaceuticals, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will AUPH stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +5.8% from the last close, and Ticker Nerd's factor model ranks Aurinia Pharmaceuticals, Inc. 92 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AUPH stock forecast for 2030?

No analyst covering Aurinia Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AUPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $21 over the next 12 months.

How has AUPH stock performed over the past year?

Aurinia Pharmaceuticals, Inc. returned +30.7% over the 12 months to 8 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aurinia Pharmaceuticals, Inc. do?

Aurinia Pharmaceuticals is a Canadian biopharmaceutical company, based in Edmonton, that develops and sells LUPKYNIS, an oral treatment for adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Its main pipeline candidate is aritinercept, a dual inhibitor targeting B cell-activating factor and proliferation-inducing ligand, for autoimmune indications.

What is the latest news on AUPH?

The most recent item we track (Zacks Investment Research, 20 Aug 2026): "Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises". Aurinia Pharmaceuticals settled its voclosporin patent litigation with Teva. The settlement delays potential generic competition in the United States until December 2036, and the company's stock rose following the news.

Why is the trailing price-to-earnings ratio only 7.05?

As of 8 September 2026, trailing net income of $314.1 million nearly matches trailing revenue of $311.5 million, which puts the TTM profit margin above 100%. The December 2025 quarter reported net income of $210.8 million, mostly from below the operating line; our earnings-quality subscore of 15.9 is the reading that flags it.

Company

About Aurinia Pharmaceuticals, Inc.

Aurinia Pharmaceuticals is a Canadian biopharmaceutical company, based in Edmonton, that develops and sells LUPKYNIS, an oral treatment for adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Its main pipeline candidate is aritinercept, a dual inhibitor targeting B cell-activating factor and proliferation-inducing ligand, for autoimmune indications. Aurinia serves patients and providers in the United States and Japan, employs 128 people, and reported trailing-twelve-month revenue of $311.5 million through June 2026.

CEO Mr. Kevin C. Tang · 128 employees · Canada · https://www.auriniapharma.com